MedTrace Logo

A Trial In Patients With Advanced Cancer And Leukemia

NCT00878189 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Conditions

  • Neoplasms by Histologic Type

Interventions

DRUG

PF-03084014

10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-25
Primary Completion
2013-01-10
Completion
2016-11-22

Countries

  • United States
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878189 on ClinicalTrials.gov